Cello Therapeutics Received IND Clearance by FDA for its First-in-Class Cellular Nanoparticle (CNP) based Immunotherapy, CE120, to Enter Clinical Phase.

On November 30, 2023, Cello Therapeutics, Inc. received IND clearance from the U.S. Food and Drug Administration (FDA) for its first immunotherapy nanoformulation CE120 to initiate first-in-human clinical trials for a variety of solid tumors. CE120 is the first innovative nanomedicine cleared for clinical trials that employs platelet membrane-coated nanoparticles for drug delivery, offering a dual benefit of tumor elimination and the potential for long-term cancer immunity in patients.

CE120 is a broad-spectrum therapeutic cancer nanovaccine developed by Cello Therapeutics, Inc. based on the Cellular Nanoparticle (CNP) drug delivery technology platform with independent intellectual property rights, and the biomimetic design concept. CE120 comprises an enriched platelet cell membrane coating on polymeric nanoparticles carrying a potent immunotherapy drug. Leveraging the inherent biological functionality of platelets, CE120 achieves targeted delivery and prolonged residence within tumor tissues after local administration. Through a gradual drug release mechanism, CE120 effectively triggers the body's anti-tumor immune response, addressing issues associated with poor therapeutic outcomes, safety concerns, and side effects linked to excessive systemic exposure.

Cello Therapeutics, Inc. (Cello) is a leading biomedical company focused on developing novel nanoparticle delivery platforms for cancer treatment. Our cellular nanoparticles (CNPs) are comprised of three main components—drug payload, biocompatible polymer, and natural cellular membrane. The payload could be a chemotherapy or immunomodulatory agent, mRNA or siRNA. The drugs are loaded within the biodegradable polymer core, which is then coated with membrane derived from human cells. This cell membrane coating technology is a recent breakthrough in the field of nanomedicine. Our target is to treat all types of cancers with a single delivery platform.

Scroll to Top